Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201721 · ClinicalTrials.gov registry record · Phase 2
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
A Phase 2 study of B-Chronic Lymphocytic Leukemia, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT00201721 is a Phase 2 study of B-Chronic Lymphocytic Leukemia that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00201721, a Phase 2 study of B-Chronic Lymphocytic Leukemia, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Pentostatin
Study Locations (1)
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201721
The ClinicalTrials.gov registry entry for NCT00201721 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00201721 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00201721 about?
NCT00201721 is a clinical study titled "Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia". This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients
What is the current status of trial NCT00201721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2002-07. Estimated completion is 2006-09.
What conditions does trial NCT00201721 study?
This clinical trial studies the following conditions: B-Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT00201721?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Pentostatin (DRUG).
Who is sponsoring clinical trial NCT00201721?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00201721 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.